RYSTIGGO 140 mg/mL, solution injectable — 1 flacon en verre de 2 mL
Medicine package · Base de données publique des médicaments (BDPM), ANSM, HAS et Assurance Maladie · France
-
CIP13
3400930284742 -
CIP7
3028474 -
CIS
68822785 -
Registration number
EU/1/23/1780
What the source publishes
- Holder
- UCB PHARMA BELGIQUE
- Active ingredients
- ROZANOLIXIZUMAB
- Form
- solution injectable
- Package
- 1 flacon en verre de 2 mL
- Routes
- sous-cutanée
- Administrative status
- authorised
- Supply regime
- prescription réservée aux spécialistes et services NEUROLOGIE ; médicament nécessitant une surveillance particulière pendant le traitement ; prescription hospitalière ; liste I ; l'administration du 1 er cycle et de la 1 ère injection du 2 ème cycle doit être réalisée en milieu hospitalier
- Marketing status
- Déclaration de commercialisation
- Authorised on
- 2024-01-05
- Prescription
- Prescription or restricted
Names this record is found by
- RYSTIGGO 140 mg/mL, solution injectable — 1 flacon en verre de 2 mL
- RYSTIGGO 140 mg/mL, solution injectable
- ROZANOLIXIZUMAB
Complete source data
{
"cis": "68822785",
"cip7": "3028474",
"form": "solution injectable",
"name": "RYSTIGGO 140 mg/mL, solution injectable — 1 flacon en verre de 2 mL",
"cip13": "3400930284742",
"holder": "UCB PHARMA BELGIQUE",
"routes": [
"sous-cutanée"
],
"holders": [
"UCB PHARMA BELGIQUE"
],
"currency": "EUR",
"marketed": true,
"bdmStatus": null,
"useDomain": "unknown",
"publicPrice": "7320.86",
"authorisedOn": "2024-01-05",
"compositions": [
{
"name": "ROZANOLIXIZUMAB",
"nature": "SA",
"strength": "140 mg",
"linkageNumber": "1",
"substanceCode": "25835",
"dosageReference": "1 mL de solution",
"pharmaceuticalElement": "solution"
}
],
"sourceStatus": "Présentation active",
"supplyRegime": "prescription réservée aux spécialistes et services NEUROLOGIE ; médicament nécessitant une surveillance particulière pendant le traitement ; prescription hospitalière ; liste I ; l'administration du 1 er cycle et de la 1 ère injection du 2 ème cycle doit être réalisée en milieu hospitalier",
"dispensingFee": "1.02",
"medicinePrice": "7319.84",
"regionalRules": "not-collected",
"targetSpecies": [],
"specialityName": "RYSTIGGO 140 mg/mL, solution injectable",
"marketingStatus": "Déclaration de commercialisation",
"publicationDates": {
"CIS_bdpm": "2026-01-08",
"CIS_CIP_bdpm": "2026-11-19",
"CIS_CPD_bdpm": "2026-01-08",
"CIS_COMPO_bdpm": "2026-01-08"
},
"specialityListed": true,
"useDomainEvidence": {
"basis": "unreviewed",
"field": null,
"value": null,
"version": 1,
"sourceId": "fr.ansm.bdpm"
},
"collectiveApproval": "oui",
"packageDescription": "1 flacon en verre de 2 mL",
"patientEligibility": "not-assessed",
"reimbursementRates": [
"65 %"
],
"marketingDeclaredOn": "2024-05-06",
"targetSpeciesStatus": "not-reported",
"additionalMonitoring": true,
"administrativeStatus": "authorised",
"prescriptionCategory": "prescription-or-restricted",
"activeIngredientNames": [
"ROZANOLIXIZUMAB"
],
"authorisationProcedure": "Procédure centralisée",
"prescriptionConditions": [
"prescription réservée aux spécialistes et services NEUROLOGIE",
"médicament nécessitant une surveillance particulière pendant le traitement",
"prescription hospitalière",
"liste I",
"l'administration du 1 er cycle et de la 1 ère injection du 2 ème cycle doit être réalisée en milieu hospitalier"
],
"reimbursementIndications": null,
"authorisationSourceStatus": "Autorisation active",
"europeanAuthorisationNumber": "EU/1/23/1780",
"presentationAdministrativeStatus": "authorised"
}
Read this record from your own software
The same record, with every field and its provenance, is one request away. An API key is free and works immediately.
curl -G "https://api.medifontis.com/v1/drugs/record" \
-H "Authorization: Bearer $MEDIFONTIS_API_KEY" \
--data-urlencode "country=fr" \
--data-urlencode "sourceId=fr.ansm.bdpm" \
--data-urlencode "id=fr:ansm:packages:3400930284742"